NCT07577583尚未招募不适用
Long-term Follow-up (LTFU) of Study Participants Who Received Azer-Cel, An Allogeneic Chimeric Antigen Receptor T-Cell Product, in a TG Therapeutics, Inc., Clinical Study
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 32
研究概览
简要总结
The main objective of this study is to collect data on the long-term safety of azer-cel, primarily through the capture of clinical events of interest (CEI) for up to 15 years following participation in TG-Azercel -101 study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 62 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Received at least 1 dose of azer-cel in TG-Azercel -101 study.
- •Signed informed consent form (ICF).
- •Willingness and ability to adhere to the study schedule and all other protocol requirements.
- •Exclusion Citeria:
- •1. No unique
排除标准
- •apply to this study.
研究者
相似试验
Enrolling By Invitation
不适用
"Real-world Assessment of BP Control in Patients With Hypertension by the Netrod RDN System" - REACH-RDNHypertensionNCT07273877Shanghai Golden Leaf MedTec Co. Ltd1,000
招募中
3 期
An Open-label Study of Azetukalner in Bipolar I or II DepressionDepressive episodes associated with Bipolar disorder I or II (Bipolar Depression)2025-522872-10-00Xenon Pharmaceuticals Inc.70
招募中
3 期
Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects2023-508804-39-00Takeda Development Center Americas Inc.32
招募中
4 期
Study to allow access to dabrafenib and/or trametinib for subjects that are benefiting from dabrafenib and/or trametinib treatment in a Novartis or GSK sponsored study.2023-509318-13-00Novartis Pharma AG17
招募中
3 期
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508delCystic Fibrosis2024-515637-14-00Vertex Pharmaceuticals Inc.295